Curis, Inc. (CRIS)

Check out top investors' recommendation for CRIS
Last closing price (Jul 29 4:00 EDT):
1.80 (1.69%) ? 
Last closing price is the stock price upon last market close (date specified in parenthesis).
Return to date (1m/3m/6m/12m):
-20.35% ? 
Return to date is the stock return for the specified period of time.
Consensus price target (1m/3m/6m/12m):
3.00
 ? 
Consensus price target is the average analyst price target for a specified period of time.
Buy/Sell Mix (1m/3m/6m/12m):
100%/0%
 ? 
Buy/sell mix the percentage mix between Buy and Sell recommendations for a given company or a research firm. Hold recommendations are excluded.
Description:
Curis, Inc. engages in the research, development, and commercialization of cancer therapeutics. Its principal product is Erivedge capsule for treatment of adults with basal cell carcinoma (BCC) that has spread to other parts of the body or that has come back after surgery. The company also develops Erivedge, which is in phase II clinical trial for the treatment of operable nodular BCC; CUDC-427, a small molecule that has completed phase I clinical trial to promote cancer cell death in breast cancer and other solid tumors, and hematological cancers; and CUDC-907, a small molecule, which is in phase I clinical trial for the treatment of advanced lymphoma and multiple myeloma. In addition, it develops CUDC-101 that has completed phase I dose escalation clinical trial for the treatment of refractory solid tumors; and phase I expansion trial for the treatment of breast, gastric, head and neck, liver, or non-small cell lung cancers. Further, the company develops Debio 0932 that is in phase Ib expansion study for the treatment of solid tumors; and in a phase I/II clinical trial for the treatment of advanced non-small cell lung cancer. It has collaborations with Genentech, Inc. for the development of Erivedge; and Debiopharm S.A. for the development and commercialization of Debio 0932. Curis, Inc. was founded in 2000 and is headquartered in Lexington, Massachusetts.
Sector:
Industry:
Analyst
An analyst is a professional research analyst or an Investor Wand user who issued a recommendation for a given company.
Research Firm
A Research Firm is a company that researches and rates stocks and publishes recommendations.
Signal
Signal is a recommendation issued by an analyst. Investor Wand considers two types of recommendations: BUY and SELL.
Signal Date
A signal date is a date when a BUY or SELL recommendation was issued for given security.
Initial Price
Initial Price is the first closing price for a specified company upon recommendation release. If the recommendation is issued in after-market hours, the Initial Price is the next day’s closing price (for a given symbol). In case of dividend distributions and stock splits, Initial Price is adjusted.
Price Target
A Price Target is an analyst’s projection of a company’s stock price by the end of the recommendation period. It represents the price at which the analyst would exit his or her existing position.
Closing Date
Closing Date is the expiration date of a recommendation. The validity timeframe of a professional analyst’s recommendation is 12 months. Investor Wand analysts can set their recommendation timeframe to one, three, six, or 12 months.
Return
The return on a single open recommendation is calculated as the maximum of the current return (based on the latest closing price) and the target price return, if the symbol reached the target. The return on a single closed recommendation is calculated as the maximum of the return on the closing date (at the end of recommendation timeframe) and the target price return, if the stock hit the target price. The return is adjusted for one-time events (e.g., stock splits).
Boris Peaker Oppenheimer & Co. Buy   May 09, '14   2.01  3.00  May 09, '15  -10.45% 
Adnan Butt RBC Capital Markets Buy   Aug 14, '13   4.09  7.00  Aug 14, '14  -55.99% 
Edward Tenthoff Piper Jaffray Buy   Sep 09, '12   4.21  7.00  Sep 09, '13  1.90% 
Brian Skorney Brean Murray, Carret & Co. Buy   Jan 30, '12   4.75  6.00  Jan 30, '13  -35.58% 
Ling Wang Summer Street Research Buy   Jan 30, '12   4.75  7.00  Jan 30, '13  -35.58% 
Boris Peaker Oppenheimer & Co. Buy   Dec 08, '11   3.56  6.00  Dec 08, '12  -14.33% 
Ling Wang Summer Street Research Buy   Oct 05, '11   3.26  5.00  Oct 05, '12  53.37% 
Ling Wang Summer Street Research Buy   Oct 05, '11   3.26  5.00  Oct 05, '12  53.37% 
Ed Arce Mcnicoll, Lewis, & Vlak Buy   Sep 21, '11   3.00  8.50  Sep 21, '12  43.67% 
Brian Skorney Brean Murray, Carret & Co. Buy   Apr 28, '11   4.39  5.00  Apr 28, '12  13.90% 
Brian Skorney Brean Murray, Carret & Co. Buy   Mar 20, '11   3.25  5.00  Mar 20, '12  53.85%